Search
07 Sept 2025
Search
07 Sept 2025
Please allow ads as they help fund our trusted local news content.
Kindly add us to your ad blocker whitelist.
If you want further access to Ireland's best local journalism, consider contributing and/or subscribing to our free daily Newsletter .
Support our mission and join our community now.
To continue reading this article, you can subscribe for as little as €0.50 per week which will also give you access to all of our premium content and archived articles!
Alternatively, you can pay €0.50 per article, capped at €1 per day.
Thank you for supporting Ireland's best local journalism!
A lack of awareness of bile duct cancer “frequently” prevents patients from accessing treatment, a charity has warned.
Only one in five (20%) patients have their cancer caught early, which means they are often unable to access treatments, according to the AMMF charity.
The charity warned that prognosis for patients with cholangiocarcinoma (a liver cancer occurring within the bile ducts) is “dismal” and said that increasing rates of disease may mean it will no longer be classed as a “rare” cancer.
Cholangiocarcinoma (CCA) is a primary liver cancer with one of the worst prognoses of any cancer. CCA deserves greater focus & investment & alongside the @CharityAMMF, we’re committed to understanding the disease further and to develop more effective treatments. #WorldCCADay pic.twitter.com/5busAP2Uyb
— AstraZenecaUK (@ASTRAZENECAUK) February 15, 2024
Half (51%) of NHS patients in England are not given any treatment after diagnosis, the charity said.
On average just 12% of patients are given surgery – the only current cure for this type of cancer, according to a study published in December last year.
AMMF is calling for more to be done to prevent the cancer from being missed, misdiagnosed and diagnosed late.
The first new treatment for the disease in 12 years was approved for use in the NHS in January.
AstraZeneca’s durvalumab, an immunotherapy which shrinks or slows the growth of tumours, was approved for use among patients with advanced cholangiocarcinoma.
51% of diagnosed #cholangiocarcinoma patients receive no cancer treatment at all.
At #AMMF’s Westminster reception on 20 February, Elliot Colburn MP welcomes key stakeholders to #RethinkLiverCancer and shift the dial on improving access to care.#bileductcancer #livertwitter pic.twitter.com/w9GY4TUrSw
— AMMF (@CharityAMMF) February 16, 2024
AMMF said that the treatment, which is taken alongside chemotherapy, offers “enormous hope” to patients who are not considered suitable for surgery.
The charity’s chief executive, Helen Morement, said: “With widespread inconsistencies in the diagnosis and management of cholangiocarcinoma occurring across the country, and new treatments evolving all the time, it is essential that GPs and teams working on the NHS front line know how to better recognise, diagnose and treat cholangiocarcinoma.”
The charity’s new paper, Rethink Liver Cancer, states that the cancer has one of the “worst prognoses of any cancer”.
“AMMF has seen first-hand how a lack of awareness of this disease so frequently prevents patients from accessing the treatments and care they need and deserve,” the authors wrote.
According to Cancer Research UK, around 2,800 people are diagnosed with bile duct cancer each year in England.
Subscribe or register today to discover more from DonegalLive.ie
Buy the e-paper of the Donegal Democrat, Donegal People's Press, Donegal Post and Inish Times here for instant access to Donegal's premier news titles.
Keep up with the latest news from Donegal with our daily newsletter featuring the most important stories of the day delivered to your inbox every evening at 5pm.
This publication supports the work of the Press Council of Ireland and Office of the Press Ombudsman, and our staff operate within the Code of Practice of the Press Council. You can obtain a copy of the Code, or contact the Council, at www.presscouncil.ie, Lo-call 1800 208 080 or email: info@presscouncil.ie.
